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Abstract. The experiment was carried out in female white Wistar rats. The effects of recombinant 
erythropoietin, rosuvastatin and their combination were investigated based on the blood supply to 
the bone after a modelled experimental osteoporosis. It was found that the studied drugs prevent 
decrease of bone microcirculation in cases of osteoporosis and in callus tissue in experimental 
osteoporotic fractures, positively influencing the course of reparative regeneration of bone tissue.  
Keyword: osteoporosis, osteoporotic fracture, microcirculation, endothelial dysfunction, 
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Introduction 
Osteoporosis is a systemic disease of skeleton, 
characterized by decrease in density of bone mass 
and microarchitecture defects in bone tissue that 
leads to high bone fragility and fracture risks. 
Osteoporosis development is based on imbalance of 
two processes of bone remodelling: resorption and 
regeneration [1, 2].  
The number of operative treatment of bone 
fractures using different implants is growing every 
year, including the use of endoprosthesis for large 
joints. According to recent investigations, each fifth 
operation of primary endoprosthesis replacement 
includes one re-endoprosthesis manipulation. This is 
generally connected with the development of aseptic 
instability because of osteoporotic abnormalities in 
bone tissue [3].  
The blood supply in the bone plays a significant 
role in the processes of bone remodelling and 
reparative regeneration of bone tissue. Bone 
microvessels have only endothelium and don’t have 
muscular or connective layers. This means that the 
endothelium mediates all humoral regulation between 
osteoblasts, osteoclasts and blood [4, 5, 6].  
The reason for a poor blood circulation of bone 
tissue can be endothelial dysfunction, that reduces 
microcirculation and leads to osteopenia and 
gradually to osteoporosis [7, 8].  
In case of endotheliotropic therapy we can 
observe the improvement of microcirculation and the 
changes of bone tissue structure [9, 10].  
It is widely known that recombinant 
erythropoietin and rosuvastatin have endotheliotropic 
effect, however their influence on bone tissue has not 
been properly investigated, what leads to further 
studies of these medicines. 
Objectives. To study the level of 
microcirculation in bone tissue in case of 
experimental osteoporosis and osteoporotic fractures 
using treatment with recombinant erythropoietin and 
rosuvastatin or their combination.  
Methods and materials. For the experiment, 
240 female white Wistar rats (200 – 250 gr) were 
used. All the manipulations were done under 
anaesthesia (by intraperitoneal introduction of a 
solution of chloral hydrate at a dose of 300 mg/kg). 
The animals were divided into twelve groups –  
20 rats each.  
I – intact – false bilateral ovariectomy was 
performed (laparotomy incision without removal of 
the ovaries was done followed with layer-by-layer 
stitching of the wound).  
II – control – bilateral ovariectomy was 
performed (laparotomy incision with removal of the 
ovaries was done followed with layer-by-layer 
stitching of the wound). 
III – Treatment with recombinant erythropoietin 
was given eight weeks after the ovariectomy and the 
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development of osteoporosis. (50 IU/kg 
subcutaneously once a week from the ninth to the 
twelfth week). 
IV – Treatment with rosuvastatin was given 
eight weeks after ovariectomy (0,86 mg/kg daily 
intraperitoneally from the tenth to the twelfth week). 
V – Treatment with recombinant erythropoietin 
and rosuvastatin was given eight weeks after bilateral 
ovariectomy using the same method as in groups III 
and IV. 
VI – Bivalos (strontium ranelate), a drug for 
comparison, was administered  eight weeks after 
bilateral ovariectomy (171 mg/kg daily 
intraperitoneally from the tenth to the twelfth week). 
VII – Eight weeks after a false bilateral 
ovariectomy a proximal femoral metaphysis fracture 
was performed; 
VIII – Eight weeks after bilateral ovariectomy a 
proximal femoral metaphysis  fracture (osteoporotic 
fracture) was performed.  
IX – Eight weeks after bilateral ovariectomy a 
proximal femoral metaphysis fracture was 
performed. After that recombinant erythropoietin 
treatment was given. (50 IU/kg subcutaneously, once 
a week from the tenth to the twelfth week). 
X – Eight weeks after bilateral ovariectomy a 
proximal femoral metaphysis  fracture was 
performed. After that rosuvastatin treatment was 
given (0,86 mg/kg daily intraperitoneally from the 
ninth to the twelfth week). 
XI – Eight weeks after bilateral ovariectomy a 
proximal femoral metaphysis fracture was 
performed. After that a recombinant erythropoietin 
and rosuvastatin therapy was given, as described for 
groups IX and X.  
XII – Eight weeks after bilateral ovariectomy a 
proximal femoral metaphysis fracture was 
performed. After that Bivalos (strontium ranelate) 
was administered (171 mg/kg daily intraperitoneally 
from the tenth to the twelfth week). 
In fracture modelling closed technique was used 
(proposal for technical improvement № 1975-11 
from 15.11.2011. “A closed technique for a 
metaphysis  fracture model for small laboratory 
animal”). A cutting blade with silicon tubes on the 
cutting edges was used, external force was applied on 
proximal femoral metaphysis until the characteristic 
signs of fracture were present (specific pathologic 
movements, fractured fragment crepitation, limb axis 
change) the load was applied perpendicular to the 
limb axis. The fracture was stabilised and fixed by 
screw clamp and twist drill needle from the distal to 
proximal part of the femur, intramedullary through 
the bone canaliculus and was firmly fixed in cortical 
layer of proximal part of the femur. The control was 
done by the absence of pathological movements in 
the fractured area. The extending part of the needle 
was shortly cut. The wound was sutured by one stitch 
through all layers. 
Twelve weeks (on the eighty-fifth day) after the 
beginning of the experiment the measurement of 
microcirculation level in bone tissue was performed. 
The measurement was done in proximal femoral 
metaphysis by laser Doppler  flowmeter (LDF). In 
the cortical layer of bone tissue a hole of 2-3mm 
deep (in the group of animals without fracture) was 
made. For animals with a fracture, the hole was made 
in callus tissue formed after the femoral fracture. A 
needle sensor was used for the microcirculation 
measurement. In the trial rats from groups I, II, III, 
IV, V and VI  some probes were taken without 
changing the position of the sensor: for endothelium 
dependent vasodilation (in response to a single 
intravenous dose of acetylcholine solution at a dose 
of 40 µg/kg), and for endothelium independent  
vasodilation (in response to a single intravenous dose 
of sodium nitroprusside solution at a dose of  
30 µg/kg). 
To confirm the role of endothelial dysfunction in 
the development of regional microcirculation 
disorders the endothelial dysfunction coefficient 
based on the laser Doppler flowmeter data was 
calculated. Endothelial dysfunction coefficient was 
defined as the ratio of the area of triangle above the 
curve of  microcirculation restoration in the response 
to nitroprusside administration to the area of triangle 
above the curve of  microcirculation restoration in 
the response to acetylcholine administration. The 
parameters of microcirculation were taken by laser 
Doppler flowmeter Biopac systems MP150 and sensor 
TSD144. The data of laser Doppler flowmeter was 
processed and recorded by software AcqKnowlwdge 
version 3.9 – 4.2,  microcirculation was measured in 
perfusion units (PU).  
The descriptive statistics and statistical analysis 
of initial research data were processed in Microsoft 
Excel. The group data was used to calculate the 
average value (M) and error of the mean (m). 
Assessment of the statistical significance of 
differences between groups was based on “two-
sample t-test with different variances”. The 
differences were considered statistically significant 
for values of p <0,05.  
Results. The experiment showed that twelve 
weeks after the operation intact animals had the 
microcirculation level in proximal femoral 
metaphysis (99,91±3,41 PU), statistically more 
significant than in the control group with 
osteoporosis (58,75±3,76 PU). Animals with 
osteoporosis had  a higher endothelial dysfunction 
coefficient (2,57±0,23) compared to intact animals  
(1,28±0,18). This larger values prove that there are 
 Rajkumar, D.S.R. Study of the microcirculation level in bone with osteoporosis and osteoporotic 
fractures during therapy with recombinant erythropoietin, rosuvastatin and their 
combinations / D.S.R. Rajkumar, O.S. Gudyrev, A.V. Faitelson, M.V. Pokrovskii // Research 
result: pharmacology and clinical pharmacology. – 2015. – V.1, №4 (6). – P. 57-60 
59 
 
RESEARCH RESULT:  
PHARMACOLOGY AND CLINICAL PHARMACOLOGY 
signs of endothelial vessel dysfunction. The 
endothelial dysfunction of bone vessels and low 
microcirculation parameters lead to an imbalance of 
bone remodelling processes that causes and 
stimulates osteoporotic changes.  
The experimental osteoporosis therapy using 
recombinant erythropoietin and rosuvastatin and their 
combinations has shown an improvement in 
microcirculation of proximal femoral metaphysis of 
laboratory animals (80,27±3,05 PU, 81,88±3,39 PU and 
86,30±2,75 PU respectively), compared to the use of 
the reference product Bivalos (67,48±2,98 PU, 
p=0,077). In case of using recombinant erythropoietin 
and rosuvastatin and their combinations endothelial 
dysfunction coefficient was statistically smaller 
compared to the control group (1,70±0,21, 1,72±0,18 
and 1,69±0,23 respectively). The product for 
comparison Bivalos, according to endothelial 
dysfunction coefficient statistics, did not have any 
endothelial protective activity (EDC = 2,44±0,19). 
In animals with models of experimental 
osteoporosis of proximal femoral metaphysis reparative 
regeneration processes in cases of osteoporosis had 
statistically smaller parameters of microcirculation in 
callus tissue (66,59±3,61 PU), compared to animals 
with fractures, but without osteoporosis (89,30±4,75 
PU). The fracture union in animals  with osteoporotic 
femoral fractures occurred in 55% of cases, while in 
cases without osteoporosis in 75%.  
The osteoporotic fracture therapy using 
recombinant erythropoietin, rosuvastatin and their 
combination has shown higher parameters of  
microcirculation in callus tissue of proximal femoral 
metaphysis fractures of laboratory animals 
(96,31±3,16 PU, 94,34±2,54 PU and 101,05±2,75 PU 
respectively). These parameters were statistically 
more significant than in other experimental and 
control groups. In cases of usage of comparative 
product (Bivalos) was observed a tendency of 
microcirculation improvement in fracture callus 
tissue in proximal femoral metaphysis but this 
numbers were not statistically significant 
(70,39±2,39 PU, p=0,386). Experimental fracture 
union using all  mentioned medical products occurred 
in 100%  of the cases.  
Discussion. Endothelial dysfunction is 
characterized by imbalance between vasoconstrictive 
and vasodilator ability of the vessels. The cause is based 
on the imbalance between vasodilative and 
vasoconstrictive factors such as nitrogen oxides (NO) 
and prostacyclin, endothelin-1 and angiotensin II [11]. 
Vascular endothelium of bone tissue is an important 
part of the bone, it has a central regulatory role [12]. 
Many clinical trials and experimental investigations 
showed that recombinant erythropoietin is a 
multifunctional trophic factor, it has different sites of 
expression, specific tissue regulation and some other 
transmissions. Erythropoietin functional receptors were 
found not only on red blood cells membranes of bone 
marrow, but also on the myeloid cells, lymphocytes, 
megalokaryocytes and also on endothelial, mesangial 
and smooth muscle cells and neurons [13]. Also 
recombinant erythropoietin promotes proliferation of 
endotheliocytes, liver embryonic stem cells and 
unstriated muscles [14, 15, 16]. The perspective of 
recombinant erythropoietin usage in cardiology is 
explained by its pleiotropic effects. In this way 
recombinant erythropoietin stimulates epithelial 
apoptosis, cardiac hypertrophy reduction, and increase 
in physical activity tolerance in patients with chronic 
cardiac failure [17, 18]. The researches on the heart of 
experimental rats showed that the treatment based on 
recombinant erythropoietin leads to coronary perfusion 
improvement, decreasing in left ventricular end 
diastolic pressure and improvement of its systolic 
function [19]. This effect is connected with endothelial 
NO-synthase and protein kinase B activation, that 
mediates phosphorylation, leading to long-term NO-
dependent vasodilation [20]. The positive influence of 
statins on endothelial function was investigated. 
Through protein kinase B activation  and influencing 
phosphorylation process in endothelial cells, eNO 
(endothelial synthase NO) causes high level of NO 
production [21], that leads to NO-dependent 
vasodilation. All stated above proves that recombinant 
erythropoietin and rosuvastatin have a positive 
influence on vascular endothelium and improvement of 
regional microcirculation of bone tissue.  
Conclusion: 
1. Twelve weeks after the bilateral ovariectomy 
the laboratory animals had the signs of vascular 
endothelial dysfunction, including bone tissue 
microvasculature, with the decrease in regional 
microcirculation parameters, that can negatively 
influence the balance on bone regeneration and 
resorption leading to osteoporosis.   
2. The recombinant erythropoietin therapy (50 
IU\kg subcutaneously, once a week from the tenth to 
the twelfth week) and rosuvastatin treatment (0,86 
mg/kg daily intraperitoneally from the ninth to the 
twelfth week) or their combination twelve weeks 
after bilateral ovariectomy showed the signs of their 
endothelial protective functions. This leads to the 
decrease in EDC and to the increase of the 
microcirculation in the bone tissue of proximal 
femoral metaphysis. The product used for 
comparison, Bivalos, has not shown any endothelial 
protective activity. 
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3. The fracture adherence of proximal femoral 
metaphysis in twelve weeks after its modelling in 
laboratory animals was accompanied by decrease of 
microcirculation parameters in callus tissue, 
consequently leading to poor consolidation 
parameters of experimental fractures.  
4. The administration of recombinant 
erythropoietin and rosuvastin and of their 
combination increased microcirculation parameters 
in callus tissue in rats with proximal femoral 
metaphysis fracture and provided favorable 
conditions for reparative regeneration, that increases 
the parameters of experimental osteoporotic fracture 
adherence. Bivalos also had a positive influence on 
the osteoporotic fracture adherence.  
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